Therapeutic options for human papillomavirus‐positive tonsil and base of tongue cancer DOI Creative Commons
Mark Zupancic,

Ourania N. Kostopoulou,

Linda Marklund

и другие.

Journal of Internal Medicine, Год журнала: 2025, Номер unknown

Опубликована: Апрель 17, 2025

Abstract The incidences of human papillomavirus‐positive (HPV + ) tonsillar and base tongue squamous cell carcinomas (TSCC BOTSCC) have increased in recent decades. Notably, HPV TSCC BOTSCC a significantly better prognosis than their HPV‐negative counterparts when treated with current surgical options, radiotherapy, or intensified chemoradiotherapy. However, cure is not achieved 20% patients TSCC/BOTSCC. Meanwhile, cured often present severe chronic side effects. This necessitates novel tailored alternatives, such as targeted therapy, immune checkpoint inhibitors (ICIs), treatment de‐escalation, together follow‐up. Current precision medicine therefore focuses on detecting predictive driver cancer genes to stratify patient treatment, provide those poor prognostic markers select favorable for de‐escalated therapy. Moreover, cell‐free DNA (cfHPV DNA) plasma before after has been attempted improve In this context, perspective discusses the significance optimally defining status, which requires p16 INKa overexpression, using markers, high CD8 T‐cell counts E2 mRNA expression, tumor size, following cfHPV selection specific therapies. Clinical trials ICI with/without chemotherapy, therapy inhibitors—such phosphoinositide 3‐kinase fibroblast growth factor receptor inhibitors—or various HPV‐based vaccines treating recurrences yielded promising results.

Язык: Английский

Therapeutic options for human papillomavirus‐positive tonsil and base of tongue cancer DOI Creative Commons
Mark Zupancic,

Ourania N. Kostopoulou,

Linda Marklund

и другие.

Journal of Internal Medicine, Год журнала: 2025, Номер unknown

Опубликована: Апрель 17, 2025

Abstract The incidences of human papillomavirus‐positive (HPV + ) tonsillar and base tongue squamous cell carcinomas (TSCC BOTSCC) have increased in recent decades. Notably, HPV TSCC BOTSCC a significantly better prognosis than their HPV‐negative counterparts when treated with current surgical options, radiotherapy, or intensified chemoradiotherapy. However, cure is not achieved 20% patients TSCC/BOTSCC. Meanwhile, cured often present severe chronic side effects. This necessitates novel tailored alternatives, such as targeted therapy, immune checkpoint inhibitors (ICIs), treatment de‐escalation, together follow‐up. Current precision medicine therefore focuses on detecting predictive driver cancer genes to stratify patient treatment, provide those poor prognostic markers select favorable for de‐escalated therapy. Moreover, cell‐free DNA (cfHPV DNA) plasma before after has been attempted improve In this context, perspective discusses the significance optimally defining status, which requires p16 INKa overexpression, using markers, high CD8 T‐cell counts E2 mRNA expression, tumor size, following cfHPV selection specific therapies. Clinical trials ICI with/without chemotherapy, therapy inhibitors—such phosphoinositide 3‐kinase fibroblast growth factor receptor inhibitors—or various HPV‐based vaccines treating recurrences yielded promising results.

Язык: Английский

Процитировано

0